Inference is the world's first agentic AI genomic discovery platform, developed by Variant Bio to revolutionize pharmaceutical research and development. By integrating proprietary and public genetic and multi-omic data with advanced AI capabilities, Inference enables R&D teams to uncover novel therapeutic targets and accelerate the development of life-saving treatments.
Key Features and Functionality:
- Agentic AI Capabilities: Inference Agents autonomously perform complex analyses, generating new insights from foundational data using first principles, rather than merely summarizing existing information.
- Comprehensive Data Integration: The platform harmonizes data from major genetic and multi-omic association studies, including numerous global biobanks and proprietary datasets from underrepresented populations, creating the largest unified source of human genomic data for drug discovery.
- Interactive Tools: Users can query live data across hundreds of millions of associations in seconds, run colocalization analyses on demand, and combine studies in real time, facilitating dynamic and iterative discovery processes.
Primary Value and Problem Solved:
Inference addresses the longstanding challenge in drug discovery of distinguishing correlation from causation. Traditional methods often identify associations without clarifying causal mechanisms, leading to inefficiencies and higher failure rates in clinical trials. By leveraging human genetics to reveal causal relationships, Inference enhances the likelihood of clinical success. Drugs with genetic support are 2.6 times more likely to succeed in clinical trials, and genetically validated targets have 50% lower odds of causing adverse effects. Inference empowers pharmaceutical companies to make informed decisions, prioritize programs with strong genetic validation, and ultimately bring effective treatments to patients more efficiently.
